[go: up one dir, main page]

UY34305A - Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar - Google Patents

Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar

Info

Publication number
UY34305A
UY34305A UY0001034305A UY34305A UY34305A UY 34305 A UY34305 A UY 34305A UY 0001034305 A UY0001034305 A UY 0001034305A UY 34305 A UY34305 A UY 34305A UY 34305 A UY34305 A UY 34305A
Authority
UY
Uruguay
Prior art keywords
heterocicles
bicyclic
derivatives
treatment
arterial hypertension
Prior art date
Application number
UY0001034305A
Other languages
English (en)
Inventor
Furet Pascal
Molteni Valentina
Thomson Christopher
Yeh Vince
Jon Christopher Loren
Bruce Ian
Chamoin Sylvie
Stephen Paul Collingwood
Furminger Vikki
Lewis Sarah
Alex Michael Saunders
Shaw Duncan
Sviridenko Lilya
Janus Diana
West Ryan
Original Assignee
Novartis Ag
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY34305(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Irm Llc filed Critical Novartis Ag
Publication of UY34305A publication Critical patent/UY34305A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Derivados de heterociclos bicíclicos de la fórmula I útiles en la inhibición de la actividad biológica mediada por el receptor PDGF en donde A es y R1, R1a, R2, R3, R4, R5, R6 y X son como se definen en la presente
UY0001034305A 2011-09-01 2012-08-30 Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar UY34305A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161530049P 2011-09-01 2011-09-01
US201261680119P 2012-08-06 2012-08-06

Publications (1)

Publication Number Publication Date
UY34305A true UY34305A (es) 2013-04-30

Family

ID=47018333

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034305A UY34305A (es) 2011-09-01 2012-08-30 Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar

Country Status (29)

Country Link
US (2) US8883819B2 (es)
EP (1) EP2751108B1 (es)
JP (1) JP5815870B2 (es)
KR (1) KR101687082B1 (es)
CN (2) CN105001218B (es)
AP (1) AP3818A (es)
AR (1) AR087755A1 (es)
AU (1) AU2012303674B2 (es)
BR (1) BR112014004631B1 (es)
CA (1) CA2845753C (es)
CL (1) CL2014000459A1 (es)
CO (1) CO6900139A2 (es)
CR (1) CR20140099A (es)
EA (1) EA024068B1 (es)
ES (1) ES2585048T3 (es)
HK (1) HK1196126A1 (es)
IL (1) IL231228A0 (es)
MA (1) MA35364B1 (es)
MX (1) MX360316B (es)
PE (1) PE20141674A1 (es)
PH (1) PH12014500407A1 (es)
PL (1) PL2751108T3 (es)
PT (1) PT2751108T (es)
SG (1) SG11201400253YA (es)
TN (1) TN2014000067A1 (es)
TW (1) TW201313718A (es)
UY (1) UY34305A (es)
WO (1) WO2013030802A1 (es)
ZA (1) ZA201401294B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
WO2015089137A1 (en) 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
CN105524058B (zh) * 2014-10-21 2018-03-27 广州艾格生物科技有限公司 吡唑并[1,5‑a]吡啶类化合物及其应用
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
GB201801355D0 (en) 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds
WO2020099929A1 (en) 2018-11-14 2020-05-22 Roivant Sciences Gmbh A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin
PH12022551429A1 (en) * 2019-12-13 2023-11-20 Nippon Shinyaku Co Ltd Compound and composition as pdgf receptor kinase inhibitor
JP7386124B2 (ja) 2020-05-28 2023-11-24 株式会社名村造船所 船舶
US20220031633A1 (en) * 2020-07-28 2022-02-03 Yale University Poly(amine-co-ester) polymeric particles for selective pulmonary delivery
TW202241914A (zh) 2020-12-23 2022-11-01 瑞士商艾克泰聯製藥有限公司 吡唑并噻唑羧醯胺及其作為ｐｄｇｆｒ抑制劑之用途
TW202313053A (zh) 2021-07-30 2023-04-01 瑞士商艾克泰聯製藥有限公司 吡唑并嘧啶及其作為ｐｄｇｆｒ抑制劑之用途
CN113912530A (zh) * 2021-11-10 2022-01-11 山东汇海医药化工有限公司 一种4-aa中间体废液的处理方法
WO2023247593A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrrolopyridine carboxamides and their uses as pdgfr inhibitors
WO2023247590A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Triazolopyridine and benzoisoxazole carboxamides and their uses as pdgfr inhibitors
WO2023247596A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
WO2023247595A1 (en) 2022-06-22 2023-12-28 Actelion Pharmaceuticals Ltd Pyrazolopyrazine carboxamides and their uses as pdgfr inhibitors
WO2024104968A1 (en) 2022-11-14 2024-05-23 Actelion Pharmaceuticals Ltd Pyrazolopyrrolopyridazines and their uses as pdgfr inhibitors

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
ZA81219B (en) 1980-01-23 1982-01-27 Schering Corp Imidazo (1,2-a) pyridines ,process for their preparation and pharmaceutical compositions containing them
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
WO1993018007A1 (en) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
JP3251587B2 (ja) 1992-04-02 2002-01-28 スミスクライン・ビーチャム・コーポレイション 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
DE59605366D1 (de) 1995-12-07 2000-07-06 Jago Pharma Ag Muttenz Inhalator zur mehrfachen dosisweisen abgabe eines pharmakologischen trockenpulvers
EP0883415B1 (en) 1996-02-21 2002-05-02 Schering Corporation Powdered medication inhaler
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
ES2215337T3 (es) 1997-12-19 2004-10-01 Schering Aktiengesellschaft Derivados de orto-antranilamida como anticoagulantes.
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
CN1146616C (zh) 1998-06-30 2004-04-21 陶氏环球技术公司 聚合物多元醇及其生产方法
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
PL345817A1 (en) 1998-08-04 2002-01-14 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
BR0009041A (pt) 1999-03-17 2001-12-26 Astrazeneca Ab Derivado de amida, processo para a preparação deum derivado de amida, composição farmacêutica,uso de um derivado de amida, e, método paratratar doenças ou quadros clìnicos mediados porcitocinas
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
IL145742A0 (en) 1999-05-04 2002-07-25 Schering Corp Piperidine derivatives useful as ccr5 antagonists
KR100439358B1 (ko) 1999-05-04 2004-07-07 쉐링 코포레이션 Ｃｃｒ5 길항제로서 유용한 피페라진 유도체
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
HU229439B1 (hu) 1999-08-21 2013-12-30 Takeda Gmbh Roflumilast és salmeterol szinergetikus kombinációja
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
IL155155A0 (en) 1999-09-17 2003-10-31 Cor Therapeutics Inc BENZAMIDES AND RELATED INHIBITORS OF FACTOR Xa
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
CN1426401A (zh) 2000-04-27 2003-06-25 贝林格尔英格海姆法玛公司 新的长效倍他米美类药物(betamimetics)其制备方法,及其作为药物组合物的用途
DK1300407T4 (da) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
SK287576B6 (sk) 2000-08-05 2011-03-04 Glaxo Group Limited S-fluórmetylester kyseliny 6alfa, 9alfa-difluór-17alfa-[(2- furanylkarboxyl)oxy]-11beta-hydroxy-16alfa-metyl-3-oxo-androsta- 1,4-dién-17beta-karbotiovej, spôsob jeho prípravy, farmaceutický prostriedok s jeho obsahom, jeho použitie a medziprodukty
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
AU2002228015B2 (en) 2000-12-22 2007-08-23 Almirall, S.A. Quinuclidine carbamate derivatives and their use as M3 antagonists
EP1353919B1 (en) 2000-12-28 2006-07-26 Almirall Prodesfarma AG Novel quinuclidine derivatives and medicinal compositions containing the same
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
SE0100568D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
SE0100567D0 (sv) 2001-02-20 2001-02-20 Astrazeneca Ab Compounds
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
IL158222A0 (en) 2001-04-30 2004-05-12 Glaxo Group Ltd Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha
ATE399174T1 (de) 2001-06-12 2008-07-15 Glaxo Group Ltd Neue anti inflammatorische 17.alpha.- heterozyklische ester von 17.beta.-carbothioat androstan derivativen
EP2039762A3 (en) 2001-06-21 2009-07-29 Verenium Corporation Nitralases
US7361787B2 (en) 2001-09-14 2008-04-22 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
EP1438309A1 (en) 2001-10-17 2004-07-21 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003048181A1 (en) 2001-12-01 2003-06-12 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
IL162596A0 (en) 2001-12-20 2005-11-20 S A L V A T Lab Sa 1-Alkyl-1-azoniabicyclo Ä2.2.2Ü octane carbamate derivatives and their use as muscarinic receptor ntagonists
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
MXPA04008790A (es) 2002-03-13 2004-11-26 Pharmacia & Upjohn Co Llc Derivados pirazolo(1,5,a)piridina como moduladores neurotransmisores.
DE60318188T2 (de) 2002-03-26 2008-12-11 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield Glucocorticoid-mimetika, deren herstellung, pharmazeutische zusammensetzungen und verwendung
JP2005521717A (ja) 2002-03-26 2005-07-21 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
AU2003221706B2 (en) 2002-04-11 2008-02-28 Merck Sharp & Dohme Corp. 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
EP1497261B1 (en) 2002-04-25 2007-12-19 Glaxo Group Limited Phenethanolamine derivatives
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
US6747043B2 (en) 2002-05-28 2004-06-08 Theravance, Inc. Alkoxy aryl β2 adrenergic receptor agonists
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
CA2490043A1 (en) 2002-06-25 2003-12-31 Merck Frosst Canada & Co. 8-(biaryl) quinoline pde4 inhibitors
CA2490097A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
SI1521733T1 (sl) 2002-07-08 2014-10-30 Pfizer Products Inc. Modulatorji glukokortikoidnega receptorja
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
JP2005538138A (ja) 2002-08-10 2005-12-15 アルタナ　ファルマ　アクチエンゲゼルシャフト Ｐｄｅ４インヒビターとしてのピリダジノン誘導体
MXPA05001354A (es) 2002-08-10 2005-04-28 Altana Pharma Ag Piperidina-ftalazonas sustituidas por pirrolidinodiona como inhibidores pde4.
WO2004018449A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
JP2005538137A (ja) 2002-08-10 2005-12-15 アルタナ　ファルマ　アクチエンゲゼルシャフト ピペリジン−ｎ−オキシド誘導体
JP2005537313A (ja) 2002-08-17 2005-12-08 アルタナ　ファルマ　アクチエンゲゼルシャフト 新規のベンゾナフチリジン
PL374014A1 (en) 2002-08-17 2005-09-19 Altana Pharma Ag Novel phenanthridines having pde 3/4 inhibiting properties
AU2003259747A1 (en) 2002-08-21 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
JP2006501236A (ja) 2002-08-23 2006-01-12 ランバクシー ラボラトリーズ リミテッド ムスカリン性レセプター拮抗薬としてのフルオロおよびスルホニルアミノ含有３，６−二置換アザビシクロ（３．１．０）ヘキサン誘導体
EP1539164B1 (en) 2002-08-29 2006-12-20 ALTANA Pharma AG 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
CA2496459C (en) 2002-08-29 2013-06-25 Altana Pharma Ag 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
EP1539141B1 (en) 2002-08-29 2010-07-14 Boehringer Ingelheim Pharmaceuticals Inc. 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
BR0314304A (pt) 2002-09-18 2005-07-26 Ono Pharmaceutical Co Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativo
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
DE60317529T2 (de) 2002-09-19 2008-09-25 Schering Corp. Imidazopyridine als hemmstoffe cyclin abhängiger kinasen
KR20050072090A (ko) 2002-09-19 2005-07-08 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리딘
US20050245588A1 (en) 2002-09-20 2005-11-03 Amjad Ali Octahydro-2-h-naphtho[1,2-f]indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EA200500618A1 (ru) 2002-10-11 2005-12-29 Пфайзер Инк. Производные индола в качестве бета-2 агонистов
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
EP1554264B1 (en) 2002-10-22 2007-08-08 Glaxo Group Limited Medicinal arylethanolamine compounds
WO2004037805A1 (en) 2002-10-23 2004-05-06 Glenmark Pharmaceuticals Ltd. Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
AU2003286143A1 (en) 2002-10-28 2004-05-13 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
AU2004207482B2 (en) 2003-01-21 2009-10-08 Merck Sharp & Dohme Corp. 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
PL377633A1 (pl) 2003-04-03 2006-02-06 Merck Patent Gmbh Związki karbonylowe
EP1479680A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Azaindole derivatives as Factor Xa inhibitors
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
CA2528851A1 (en) 2003-06-10 2004-12-16 Ace Biosciences A/S Extracellular aspergillus polypeptides
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20050171171A1 (en) 2003-11-13 2005-08-04 Ambit Biosciences Corporation Amide derivatives as FLT-3 modulators
CA2551508C (en) 2003-12-23 2011-08-09 Pfizer Inc. Novel quinoline derivatives
JP2007526324A (ja) 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
AR053992A1 (es) 2004-12-22 2007-05-30 Astrazeneca Ab Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica.
WO2006067446A1 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
US20090105250A1 (en) 2005-01-26 2009-04-23 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2006101455A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Imidazo[1,2-a]pyridine derivatives: preparation and pharmaceutical applications
GB0507575D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
CA2614156A1 (en) * 2005-07-29 2007-02-15 F. Hoffmann-La Roche Ag Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP1931641B1 (en) 2005-09-09 2010-08-25 Schering Corporation NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHI
JP2009518340A (ja) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト ＥｐｈＢおよびＶＥＧＦＲ２キナーゼ阻害剤としてのピラゾロ［１，５−ａ］ピリジン−３−カルボン酸
US20090170847A1 (en) * 2006-01-23 2009-07-02 Seung Chul Lee Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same
GB0604937D0 (en) 2006-03-10 2006-04-19 Novartis Ag Organic compounds
CN101410397A (zh) 2006-03-31 2009-04-15 诺瓦提斯公司 有机化合物
US20080015193A1 (en) 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
KR101104666B1 (ko) * 2006-09-06 2012-01-13 에프. 호프만-라 로슈 아게 단백질 키나제 억제제로서의 헤테로아릴 유도체
EP2079729A1 (en) 2006-11-03 2009-07-22 Irm Llc Compounds and compositions as protein kinase inhibitors
SI3034075T1 (sl) 2006-11-22 2018-12-31 Incyte Holdings Corporation Imidazotriazini in imidazopirimidini kot inhibitorji kinaze
CA2672213C (en) 2006-12-22 2016-02-16 Astex Therapeutics Limited Bicyclic amine derivatives as protein tyrosine kinase inhibitors
US7759344B2 (en) 2007-01-09 2010-07-20 Amgen Inc. Bis-aryl amide derivatives and methods of use
WO2008134553A1 (en) 2007-04-26 2008-11-06 Xenon Pharmaceuticals Inc. Methods of using bicyclic compounds in treating sodium channel-mediated diseases
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
TW200904816A (en) 2007-06-05 2009-02-01 Takeda Pharmaceutical Fused heterocycle derivatives and use thereof
TW201716375A (zh) 2007-06-12 2017-05-16 Achaogen Inc 抗菌劑
EP2170830B1 (en) 2007-07-17 2014-10-15 Plexxikon, Inc. 2-FLUORO-BENZENESULFONAMIDE COMPOUNDS AS Raf KINASE MODULATORS
CN101945848A (zh) 2007-12-20 2011-01-12 英维沃医药有限公司 四取代的苯
WO2009103778A1 (en) 2008-02-19 2009-08-27 Novasaid Ab Compounds and methods
KR101324804B1 (ko) 2008-05-13 2013-11-01 아이알엠 엘엘씨 키나제 억제제로서의 질소 함유 융합 헤테로사이클 및 그의 조성물
US8455477B2 (en) 2008-08-05 2013-06-04 Merck Sharp & Dohme Corp. Therapeutic compounds
EP2210891A1 (en) 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
WO2010088000A2 (en) 2009-02-02 2010-08-05 Angion Biomedica Corp. Antifibrotic compounds and uses thereof
CN102573846B (zh) 2009-08-17 2015-10-07 因特利凯公司 杂环化合物及其用途
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2579888A2 (en) 2010-06-09 2013-04-17 Receptos, Inc. Novel glp-1 receptor stabilizers and modulators
LT2593452T (lt) 2010-07-14 2017-04-10 Novartis Ag Heterocikliniai junginiai, kaip ip receptoriaus agonistai
CA2807198A1 (en) * 2010-08-03 2012-02-09 Graffinity Pharmaceuticals Gmbh Ligands for antibody and fc-fusion protein purification by affinity chromatography
JP5894161B2 (ja) 2010-08-25 2016-03-23 ネオファーム カンパニー， リミテッド 新規の複素環化合物及びこれを用いた炎症性疾患治療用組成物
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension

Also Published As

Publication number Publication date
CN105001218A (zh) 2015-10-28
EP2751108A1 (en) 2014-07-09
ES2585048T3 (es) 2016-10-03
KR20140059272A (ko) 2014-05-15
AU2012303674B2 (en) 2015-11-26
PT2751108T (pt) 2016-08-04
BR112014004631B1 (pt) 2020-02-11
US20150025059A1 (en) 2015-01-22
AR087755A1 (es) 2014-04-16
IL231228A0 (en) 2014-04-30
PL2751108T3 (pl) 2016-11-30
US8883819B2 (en) 2014-11-11
AU2012303674A1 (en) 2014-03-13
CR20140099A (es) 2014-06-25
JP5815870B2 (ja) 2015-11-17
EA024068B1 (ru) 2016-08-31
AP3818A (en) 2016-09-30
MX360316B (es) 2018-10-29
CO6900139A2 (es) 2014-03-20
WO2013030802A1 (en) 2013-03-07
MX2014002499A (es) 2014-05-30
CN105001218B (zh) 2017-04-12
US20130237519A1 (en) 2013-09-12
AP2014007539A0 (en) 2014-03-31
CL2014000459A1 (es) 2014-09-05
ZA201401294B (en) 2015-06-24
NZ621436A (en) 2015-10-30
TW201313718A (zh) 2013-04-01
TN2014000067A1 (en) 2015-07-01
EP2751108B1 (en) 2016-04-27
CN104024252A (zh) 2014-09-03
MA35364B1 (fr) 2014-08-01
CA2845753C (en) 2021-04-20
CA2845753A1 (en) 2013-03-07
JP2014527544A (ja) 2014-10-16
HK1196126A1 (zh) 2015-03-20
CN104024252B (zh) 2015-08-26
KR101687082B1 (ko) 2016-12-15
SG11201400253YA (en) 2014-03-28
EA201490543A1 (ru) 2014-07-30
PE20141674A1 (es) 2014-11-14
BR112014004631A2 (pt) 2017-03-14
US9751876B2 (en) 2017-09-05
PH12014500407A1 (en) 2017-04-07

Similar Documents

Publication Publication Date Title
UY34305A (es) Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EP3848364C0 (en) MICROBIOCIDAL HETEROBICYCLIC DERIVATIVES AND INTERMEDIATES FOR THEIR PREPARATION
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY34550A (es) Bencilpirazoles sustituidos
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
UY34374A (es) Benzilindazoles sustituidos
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34523A (es) Derivados de betulina
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34559A (es) Inhibidores de bromodominios
UY34515A (es) Triazolopiridinas sustituidas
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34034A (es) Triazolopiridinas
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210603